Pharsight

Drugs that contain Pegcetacoplan

1. Empaveli patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9169307 APELLIS PHARMS Potent compstatin analogs
Nov, 2027

(3 years from now)

US7989589 APELLIS PHARMS Compstatin analogs with improved activity
Dec, 2027

(3 years from now)

US7888323 APELLIS PHARMS Potent compstatin analogs
Dec, 2027

(3 years from now)

US11661441 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Jan, 2033

(8 years from now)

US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(9 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US11292815 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11040107 APELLIS PHARMS Dosing regimens and related compositions and methods
Apr, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 14, 2026
Orphan Drug Exclusivity(ODE-351) May 14, 2028
M(M-288) Feb 08, 2026

NCE-1 date: 14 May, 2025

Market Authorisation Date: 14 May, 2021

Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly; Treatment of adult patients with paroxysmal nocturnal hemoglobinu...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

EMPAVELI family patents

Family Patents

2. Syfovre patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9169307 APELLIS PHARMS Potent compstatin analogs
Nov, 2027

(3 years from now)

US7888323 APELLIS PHARMS Potent compstatin analogs
Dec, 2027

(3 years from now)

US7989589 APELLIS PHARMS Compstatin analogs with improved activity
Dec, 2027

(3 years from now)

US11661441 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Jan, 2033

(8 years from now)

US10125171 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
Aug, 2033

(9 years from now)

US10035822 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US10875893 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

US11292815 APELLIS PHARMS Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Nov, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9056076 APELLIS PHARMS Method of treating age-related macular degeneration comprising administering a compstatin analog
Oct, 2026

(2 years from now)

US8168584 APELLIS PHARMS Methods of treating age-related macular degeneration by compstatin and analogs thereof
Apr, 2027

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Feb 22, 2026
New Chemical Entity Exclusivity(NCE) May 14, 2026

NCE-1 date: 14 May, 2025

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan; Treatment of geographic atrophy secondary to age-related macular degenera...

Dosage: SOLUTION;INTRAVITREAL

More Information on Dosage

SYFOVRE family patents

Family Patents